Document is current
Any future updates will be listed below
-
Authors
Tillmann, J. http://orcid.org/0000-0001-9574-9855
Uljarevic, M.
Crawley, D.
Dumas, G.
Loth, E.
Murphy, D.
Buitelaar, J.
Charman, T.
,
Ahmad, Jumana
Ambrosino, Sara
Auyeung, Bonnie
Baumeister, Sarah
Beckmann, Christian
Bourgeron, Thomas
Bours, Carsten
Brammer, Michael
Brandeis, Daniel
Brogna, Claudia
de Bruijn, Yvette
Chakrabarti, Bhismadev
Cornelissen, Ineke
Acqua, Flavio Dell’
Dumas, Guillaume
Ecker, Christine
Faulkner, Jessica
Frouin, Vincent
Garcés, Pilar
Goyard, David
Hayward, Hannah
Hipp, Joerg
Johnson, Mark H.
Jones, Emily J. H.
Kundu, Prantik
Lai, Meng-Chuan
D’ardhuy, Xavier Liogier
Lombardo, Michael
Lythgoe, David J.
Mandl, René
Mason, Luke
Meyer-Lindenberg, Andreas
Moessnang, Carolin
Mueller, Nico
O’Dwyer, Laurence
Oldehinkel, Marianne
Oranje, Bob
Pandina, Gahan
Persico, Antonio M.
Ruggeri, Barbara
Ruigrok, Amber
Sabet, Jessica
Sacco, Roberto
Toro, Roberto
Tost, Heike
Waldman, Jack
Williams, Steve C. R.
Wooldridge, Caroline
Zwiers, Marcel P.
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (777394)
Australian Research Council (DE180100632)
Innovative Medicines Initiative (115300)
- License Information
-
More Information
Article History
Received: 27 February 2020
Accepted: 23 July 2020
First Online: 31 August 2020
Ethics approval and consent to participate
: The study was approved by the local ethical committees of the participating centres and written informed consent was obtained from all participants or their legal guardians (for participants <18 years).
: Not applicable
: Jan K Buitelaar has been in the past years a consultant to/member of advisory board of/and/or speaker for Takeda/Shire, Roche, Medice, Servier and Angelini. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents and royalties. Julian Tillmann is a consultant to F. Hoffmann-La Roche.
